Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Meghan KaruturiDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Anas YounesDepartment of Lymphoma, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Luis FayadDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Larry KwakDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Barbara ProDepartment of Medical Oncology, Thomas Jefferson Medical College, Philadelphia, PA, USA

Jatin ShahDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yasuhiro OkiDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Rinata SimienDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Mary Joy LiboonDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Toni HuttoDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Sandra HorowitzDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yago NietoDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paolo AnderliniDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Amin AlousiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Uday PopatDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

L. Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Roberto MirandaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Michelle FanaleDepartment of Lyphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]

References